Answers are grounded in this paper and cite their sources.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that may remain inadequately controlled despite established biologic therapies. Emerging therapies targeting JAK‐1, IL‐1 and CXCR1/2 pathways have generated interest, but their efficacy and safety remain uncertain. This review aimed to evaluate the efficacy and safety of JAK‐1 inhibitors, IL‐1 pathway inhibitors, and CXCR1/2 pathway‐directed therapies in moderate–to–severe HS. Following PRISMA 2020, seven randomised controlled trials (RCTs) were synthesised. Meta‐analysis was restricted a priori to placebo‐controlled JAK‐1 inhibitor RCTs, pooling the risk ratios for Hidradenitis Suppurativa Clinical Response of at least 50% (HiSCR50) using random‐effects models (Paule–Mandel τ 2 ; Hartung–Knapp adjustment). IL‐1 and CXCR1/2 pathway findings were synthesised descriptively because of heterogeneity and small study numbers. Safety outcomes were also summarised descriptively. Across three JAK‐1 trials assessed at Weeks 8, 12 or 16, the pooled estimate favoured treatment but was not statistically significant (risk ratio [RR] 1.47; 95% confidence interval [CI] 0.95–2.27). IL‐1 pathway inhibitors demonstrated heterogeneous and imprecise effects. A single RCT of eltrekibart, which neutralises CXCR1/2 ligands, provided an early efficacy signal at Week 16 (RR 1.54; 95% CI 0.78–3.04), requiring confirmation. Safety findings were descriptive and constrained by inconsistent reporting and short blinded observation periods; they do not establish longer‐term safety. Among the included trials, JAK‐1 inhibition showed a consistent direction of effect, while IL‐1 and CXCR1/2 findings remained preliminary. Larger, longer‐duration trials and direct comparisons are needed to establish therapeutic positioning.
No takes yet. Share an insight, caveat, or question.
Nakad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: